Universität zu Köln

Panse, Jens, Toelle, Daniela, Fiegle, Eva, Naendrup, Jan-Hendrik, Schmidt-Hieber, Martin, Boell, Boris, Hentrich, Marcus ORCID: 0000-0001-5622-348X, Teschner, Daniel ORCID: 0000-0001-7351-8060 and Schalk, Enrico ORCID: 0000-0003-1892-5098 (2022). Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-study. Ann. Hematol., 101 (10). S. 2317 - 2325. NEW YORK: SPRINGER. ISSN 1432-0584

Full text not available from this repository.

Abstract

Although not generally recommended, scheduled central venous catheter (CVC) removal is sometimes carried out in order to reduce the CVC-related bloodstream infection (CRBSI) incidence. We conducted a simulation for scheduled CVC removal within the multicenter CRBSI registry (SECRECY). Non-tunneled jugular and subclavian CVC in patients with hematological disease or with germ cell tumors (including patients receiving autologous stem cell transplantation [SCT]) were included. Cases were randomized in a 1:1:1:1 ratio to either a simulated, scheduled CVC removal after 7, 14, and 21 days, or to non-simulated, unscheduled CVC removal (control group). The primary endpoint was definitive CRBSI incidence for a scheduled CVC removal after 14 days (dCRBSI-D14(rmv)). Among other, secondary endpoints were definite CRBSI incidence for a scheduled removal after 7 days (dCRBSI-D7(rmv)) and 21 days (dCRBSI-D21(rmv)). Data on 2984 CVC were included. Patients' median age was 59 (range 16-95) years, 58.8% being male. The vast majority (98.4%) were patients with hematological malignancies. Jugular veins were the main insertion site (93.2%). dCRBSI-D14(rmv) was 3.10/1000 CVC days as compared to 4.15/1000 CVC days in the control group (p = 0.23). There was a significant difference between dCRBSI-D7(rmv) (0.86/1000 CVC days) and controls (p < 0.001), but not between dCRBSI-D21(rmv) (4.10/1000 CVC days) and controls (p = 0.96). Our data suggest that in patients with hematological diseases or autologous SCT recipients scheduled CVC removal after 14 days does not result in a lower CRBSI incidence compared to unscheduled removal.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Panse, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Toelle, Daniela UNSPECIFIED UNSPECIFIED UNSPECIFIED Fiegle, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Naendrup, Jan-Hendrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt-Hieber, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Boell, Boris UNSPECIFIED UNSPECIFIED UNSPECIFIED Hentrich, Marcus UNSPECIFIED orcid.org/0000-0001-5622-348X UNSPECIFIED Teschner, Daniel UNSPECIFIED orcid.org/0000-0001-7351-8060 UNSPECIFIED Schalk, Enrico UNSPECIFIED orcid.org/0000-0003-1892-5098 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-686999
DOI:	10.1007/s00277-022-04958-w
Journal or Publication Title:	Ann. Hematol.
Volume:	101
Number:	10
Page Range:	S. 2317 - 2325
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0584
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PLATELET TRANSFUSION; RISK-FACTORS; COLONIZATION; CHEMOTHERAPY; REPLACEMENT; GUIDELINES; DIAGNOSIS; CANCER; TABLES; TRIAL Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68699